scholarly journals PMS3 COMPARISON OF 3 COMORBIDITY MEASURES AFFECTING PHYSICAL FUNCTION AND QUALITY OF LIFE FOR PATIENTS WITH ANKYLOSING SPONDYLITIS

2009 ◽  
Vol 12 (3) ◽  
pp. A64
Author(s):  
K Gooch ◽  
R Wong
Keyword(s):  
Quality Of Life ◽  
Ankylosing Spondylitis ◽  
Physical Function

scholarly journals Five Potentially Modifiable Factors Predict Poor Quality of Life in Ankylosing Spondylitis: Results from the Scotland Registry for Ankylosing Spondylitis

2017 ◽  
Vol 45 (1) ◽  
pp. 62-69 ◽  
Author(s):  
Linda E. Dean ◽  
Gary J. Macfarlane ◽  
Gareth T. Jones
Keyword(s):  
Quality Of Life ◽  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Physical Function ◽  
Spinal Mobility ◽  
Factors Associated ◽  
Modifiable Factors ◽  
Chronic Inflammatory Condition ◽  
Patient Reported

Objective.A chronic inflammatory condition manifesting in young adulthood, ankylosing spondylitis (AS) affects both physical and emotional quality of life (QOL). To inform future intervention strategies, this study aimed to (1) assess the QOL of patients with AS, and (2) identify potentially modifiable factors associated with reporting poor QOL.Methods.The Scotland Registry for Ankylosing Spondylitis collects clinical and patient-reported data on clinically diagnosed patients with AS across Scotland. QOL is measured using the ASQoL questionnaire [range: 0 (high) to 18 (poor)]. Potentially modifiable factors associated with reporting poor QOL (score 12–18) were examined using Poisson regression models, adjusted for a variety of demographic characteristics, plus various nonmodifiable factors. Results are given as risk ratios (RR) with 95% CI.Results.Data were available on 959 patients: 74% male, mean age 52 years (SD 13), median ASQoL 7.0 (interquartile range 2–12). Although many factors were univariately associated with poor QOL, 5 were identified as independent predictors: reporting moderate/severe fatigue (RR 1.60, 95% CI 1.13–2.28), poor physical function [Bath Ankylosing Spondylitis Functional Index (BASFI) ≥ 4: 3.46, 1.76–6.82], chronic widespread pain (CWP; 1.92, 1.33–2.75), high disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4: 1.52, 1.09–2.12], and poor spinal mobility [Bath Ankylosing Spondylitis Metrology Index (BASMI) ≥ 4: 1.52, 0.93–2.50]. For these factors, population-attributable risks ranged between 20% (disease activity) and 56% (physical function).Conclusion.We have identified 5 potentially modifiable factors independently associated with poor QOL. These findings provide evidence that in addition to traditional clinical targets (BASDAI, BASFI, and BASMI), focus on nonspecific symptoms (CWP and fatigue), perhaps with nonpharmacological therapies, may yield important improvements in QOL.

Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial

2013 ◽  
Vol 73 (3) ◽  
pp. 587-594 ◽  
Author(s):  
Feng Huang ◽  
Jieruo Gu ◽  
Ping Zhu ◽  
Chunde Bao ◽  
Jianhua Xu ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Physical Function ◽  
Chinese Patients ◽  
Inactive Disease ◽  
Inadequate Response ◽  
Efficacy And Safety ◽  
Chinese Adults

Background and objectivesEfficacy of adalimumab for ankylosing spondylitis (AS) has been established for Western populations but not in the Chinese population. This study is the first to evaluate the efficacy and safety of adalimumab in Chinese patients with AS.MethodsChinese adults with active AS who had an inadequate response or were intolerant to ≥1 non-steroidal anti-inflammatory drugs were randomised to adalimumab 40 mg (N=229) or matching placebo (N=115) subcutaneously every other week (EOW) for 12 weeks, followed by a 12-week open-label adalimumab 40 mg EOW phase. The primary efficacy endpoint was the percentage of patients meeting the Assessment in Spondyloarthritis International Society (ASAS20) response criteria at week 12. The recently developed AS Disease Activity Score (ASDAS), as well as efficacy measures of spinal mobility, disease activity, physical function and quality of life were evaluated.ResultsAt week 12, adalimumab treatment resulted in a significantly greater percentage of ASAS20 responders than placebo (67.2% versus 30.4%, respectively; p<0.001). Differences in ASAS20 were observed as early as week 2 (42.8% vs 6.1%, respectively; p<0.001). The percentages of patients achieving ASAS40, ASAS 5/6 and ASDAS inactive disease were significantly greater with adalimumab than placebo at week 12 (all p<0.001). Tuberculosis was reported in one patient. No cases of malignancy, lymphoma, demyelinating disease or lupus-like syndrome were reported during the study.ConclusionsAdalimumab significantly reduced the signs and symptoms, improved physical function and quality of life of Chinese patients with active AS, and was generally safe and well tolerated in this population.

scholarly journals Assessment of functional disability and quality of life in patients with ankylosing spondylitis

2009 ◽  
Vol 137 (9-10) ◽  
pp. 524-528 ◽  
Author(s):  
Dusan Mustur ◽  
Vladislava Vesovic-Potic ◽  
Dejana Stanisavljevic ◽  
Tatjana Ille ◽  
Mihailo Ille
Keyword(s):  
Quality Of Life ◽  
Mental Health ◽  
Ankylosing Spondylitis ◽  
Physical Function ◽  
Functional Disability ◽  
Rating Scale ◽  
Bodily Pain ◽  
Physical Role ◽  
Sf 36

Introduction Ankylosing spondylitis is a chronic progressive autoimmune inflammatory disorder involving mainly the axial skeleton and larger peripheral joints that progressively limits spinal mobility and may lead to irreversible structural changes and consequently to impaired physical function and reduced quality of life. Objective The aim of this study was to assess functional disability and quality of life of patients with ankylosing spondylitis and determine the correlation between functional disability and quality of life. Methods The study enrolled 74 patients with ankylosing spondylitis (16 females and 58 males). The demographic data of the patients were collected. Functional disability was assessed with the Bath Ankylosing Functional Index (BASFI). Quality of life was assessed by the Short-Form 36 (SF-36) and the European Quality of Life Questionnaire (EuroQoL/EQ-5D). Results In our study, the mean age was 48.5?10.3 years. BASFI was negatively correlated with the SF-36 physical function subscale (p<0.001), physical role (p=0.002), bodily pain (p=0.003), general health (p<0.001), vitality (p=0.012) and mental health (p=0.010) subscale. There was a significantly inverse correlation between the BASFI score and the rating scale of EQ-5D (p=0.001). In the regression model, the BASFI score (p=0.000) showed an independent association with the physical function domain of SF-36. Conclusion In conclusion, the BASFI index was associated with physical function, physical role, bodily pain, general health, vitality and mental health domains of SF-36 and also with the rating scale of EQ-5D.

Use of Rheumatic Scores to Guide Therapeutic Decisions in Patients with Ankylosing Spondylitis: Results of a Multicentre Study in Germany

2017 ◽  
Vol 42 (06) ◽  
pp. 544-550
Author(s):  
C. Hillebrecht ◽  
B. Wolff ◽  
H. Kleine ◽  
C. Baerwald ◽  
J. Kuipers
Keyword(s):  
Quality Of Life ◽  
Ankylosing Spondylitis ◽  
Multicentre Study ◽  
Disease Activity ◽  
Physical Function ◽  
Treatment Response ◽  
Therapeutic Decisions ◽  
Study Results ◽  
Activity Loss

Abstract Summary Background Rheumatology practice has seen an increasing development and use of scores to assess disease activity, loss of physical function, quality of life and radiographic damage. Study results, in particular for rheumatoid arthritis, demonstrate that target-oriented treatment concepts using scores lead to improved treatment results (Treat-to-Target). Objective To review how frequently scores are used in daily rheumatological practice to assess disease activity, loss of physical function and treatment response in patients with ankylosing spondylitis and how much treatment decisions are influenced by the use of these scores. Methods A Germany-wide prospective multicentre study 74 sites (61 rheumatologists in private practice and 13 hospital-based rheumatologists) documented the use of scores for assessing disease activity, treatment response, quality of life and imaging results in patients with ankylosing spondylitis (AS) (18–83 years) over 3 consecutive visits. A total of 1 476 fully evaluable visits of 492 patients [326 (66.26%) men and 166 (33.74%) women] were recorded. Results The most commonly used scores were BASDAI (n=1.134, 84% of all visits) and BASFI (n=500, 37.5%). At least one score was calculated in 1.335 visits (90.45%); a combination of several scores was calculated in 748 visits (50.68%). Only in 141 visits (9.55%) no scores were calculated at all. Scores were used independently of patients’ age, duration of treatment, medication, and treatment changes and region of the participating rheumatologist. Scores recording treatment response (ASAS response) or quality of life were recorded in a few cases only. The average influence of a score on a treatment decision was 5.67 on a scale from 0 to 10.

Sign in / Sign up

Export Citation Format

Share Document